Opening Remarks by the Organizer Shinichi Higashiue (Tokushukai Group)

1) Vascular regeneration therapy using adipose-derived regenerative cells (ADRC) Toyoaki Murohara (Nagoya University)

2) Clinical Experience with Korea’s First iPS Cell-Derived Injectable Chondrospheroid for Osteoarthritis Ji Hyeon Ju (The Catholic University of Korea / YiPSCELL)

3) Establishment of Next generation Autologous Tissue and Vascular Regenerative Therapy Rica Tanaka (Juntendo University) 諸事情により、アーカイブ動画の掲載は控えさせていただきます。

4) Toward Next-Generation Regenerative Platforms: Harnessing Small Blood Stem Cells and Stromal Vascular Fraction-Derived Components for Clinical Translation Yun Yen (StemBios / Taipei Medical University)

5) Biomedical application of extracellular vesicles Takahiro Ochiya (Tokyo Medical University)

1) Introduction: Introduction of Biology and Medicine in Vascular Regeneration Takayuki Asahara (Shonan Kamakura General Hospital, TIMC TOKYO)

2) Endothelial Progenitor Cells: Current Understanding, Methodological Approaches, and Insights from Single-Cell Technologies. Amankeldi Salybekov (Shonan Kamakura General Hospital)

3) Endothelial Cells and Regeneration:A Cornerstone in Hemocompatibility of Cardiovascular Biomaterials David Smadja (Paris Cardiovascular research center)

4) Mitochondrial Transfer as a Strategy to Improve ECFC-Based Vascular Therapies Juan Melero-Martin (Harvard University / Boston Children’s Hospital)

5) Expanded CD34+ cells (ProtheraCytes®) for treatment of vascular ischemic diseases Philippe R.G HENON (CellProthera / IRHT)

1) Introduction: Importance of Cancer Immune Cell Therapy and application of Exosome derived from Dendritic Cells Akihiro Shimosaka (Asian Cell Therapy)

2) A Phase 1 Clinical Trial to evaluate the Safety and Tolerability of Schwann-like cells for Charcot–Marie–Tooth type 1 (CMT1) Jaeseung Lim (Cellatoz Therapeutics)

3) JOINT-PRESERVING REGENERATIVE THERAPY: CLINICAL OUTCOMES OF AUTOLOGOUS AND ALLOGENEIC CHONDROCYTE SHEET TRANSPLANTATION Masato Sato (Tokai University)

4) Multi-organ single cell transcriptomics for cell-based therapeutic angiogenesis Oto Inoue (Kanazawa University)

5) Early results of the clinical trial (LAPiS study) to transplant human iPS cell-derived cardiomyocyte transplantation to severe heart failure due to ischemic heart disease Keiichi Fukuda (Keio University, Heartseed Inc.)

1) Tracing CD34+ Cells in the Development and Cardiovascular Diseases Qingbo Xu (Zhejiang University)

2) Long term outcomes of intracarotid arterial transfusion of circulatory-derived autologous CD34+ cells for acute ischemic stroke patients-A randomized, open-label, controlled phase II clinical trial Hon Kan Yip (Kaohsiung Chang Gung Memorial Hospital)

3) Comprehensive cell therapy for kidney disease using autologous G-CSF-mobilized peripheral blood-derived CD34+ cell administration. Takayasu Ohtake (Shonan Kamakura General Hospital)

1) Injectable Vascular organoids generate perfusable blood vessels to alleviate ischemic diseases Kai Wang (Pekin University)

2) Generation of liver sinusoidal endothelial-like cells secreting coagulation factor VIII from human iPS cells toward the cell-based therapy for hemophilia A Kohei Tatsumi (Nara Medical University)

3) Toward Global Standardization of ECFC-Based Regenerative Therapies: Manufacturing and Regulatory Perspectives Chi Young Chang (YOUTH BIO GLOBAL Co., Ltd.)

Panel Discussion Panelist: David Smadja (Paris Cardiovascular research center)
Philippe R.G HENON (CellProthera / IRHT)
Juan Melero-Martin (Harvard University / Boston Children’s Hospital)
Qingbo Xu (Zhejiang University)
Takayuki Asahara (Shonan Kamakura General Hospital, TIMC TOKYO)